Mr. Schwarzer has served as our Chief Executive Officer and a member of our Board of Directors since 2010. Mr. Schwarzer also served as a Managing Partner of Charter Life Sciences, a venture capital firm specializing in life sciences investments, for approximately 15 years. He also served as the Chair of Inviragen, the creators of the DENVax dengue vaccine, from the time of its first venture capital financing until its acquisition by Takeda. He previously served as Chief Executive Officer and then Chair of the Board of Directors of Heska Corporation, a biotechnology company. Mr. Schwarzer received a B.A. in Pre-Legal Studies from the University of Michigan and a J.D. from the University of California, Berkeley, School of Law.
Dr. Decker has served as our Chief Business Officer since 2021. Prior to joining us, Dr. Decker was Chief Business Officer at Atreca, where she led business development, including portfolio and alliance management functions. Dr. Decker has also served in multiple roles at Nektar Therapeutics, culminating in her final role as Vice President, Business Development, where she led all partnering activities including strategy, identifying and assessing new opportunities and developing deal structures and financial terms. She began her career in business development at the University of Massachusetts Medical School, where she was responsible for licensing, intellectual property strategy and management, and marketing of early stage life science inventions, including the University’s Nobel Prize winning RNAi technology. Dr. Decker received a Ph.D. in Immunology from Tufts University School of Medicine and a B.A. in Biology from the College of the Holy Cross.
Mr. Gauthier has served as our Chief Commercial Officer since 2021. Mr. Gauthier joins IGM with twenty years of experience in global commercial strategy, marketing, sales and product development. Most recently, he was Vice President of Global Product Strategy for Breast and Gynecological Cancers at Genentech, where he led a global team in the creation and execution of commercial and product development strategies. Prior to his most recent role at Genentech, Mr. Gauthier served in multiple other roles at Genentech, including Life Cycle Leader of ROZYLTREK and KADYCLA, where he developed and implemented a new commercial model for rare biomarker driven cancers. Before his time at Genentech, Mr. Gauthier served in a variety of roles at F. Hoffman-La Roche in Switzerland, including as International Business Leader for Tarceva. Mr. Gauthier received an M.B.A. from Kellogg Graduate School of Management at Northwestern University and a B.S. in Chemical Engineering from Michigan State University.
Dr. Keyt has served as our Chief Scientific Officer since 2012, after serving in that role as a consultant for us beginning in 2010. Prior to joining us, Dr. Keyt served as Chief Technology Officer at Trellis Bioscience, an antibody discovery company, from 2007 to 2010. Previously, he served as Head of Research for Abmaxis, a biotechnology company, from 2005 through its acquisition by Merck in 2006. He was also Vice President of Preclinical Development at Abgenix, a biotechnology company, from 2001 through its acquisition by Amgen in 2005. Dr. Keyt was the Director of Pharmacology at Millennium Pharmaceuticals from 1998 to 2001. From 1982 to 1998, he served in various research and leadership roles at Roche/Genentech, where he made significant contributions to the discovery and development of Avastin, Lucentis, Activase tPA, TNKase-tPA and Kogenate (Factor VIII). Dr. Keyt received a B.A. in Chemistry from Washington University in St. Louis and a Ph.D. in Biochemistry and Pharmacology from Tufts University School of Medicine.
Mr. Tahir has served as our Chief Financial Officer since 2019. Prior to joining us, Mr. Tahir was with Dermira, a biotechnology company, where he served in various roles from 2014 to 2018, most recently, as Vice President, Head of Finance. Previously, he held finance and leadership positions at various biotechnology companies, including Onyx Pharmaceuticals, Human Genome Sciences and Amgen. Mr. Tahir began his career as a management consultant at the consulting firm of Oliver Wyman, formerly Mercer Management Consulting. He received a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from the University of Michigan Business School.
Dr. Takimoto has served as our Chief Medical Officer since 2021. Dr. Takimoto joins us with 30 years of experience in cancer research and development, most recently as Senior Vice President, Oncology, Gilead Sciences. Prior to Gilead, Dr. Takimoto was Chief Medical Officer of Forty Seven, a biotechnology company formed out of Stanford University and acquired by Gilead Sciences in 2020. Dr. Takimoto has also served as Vice President of Experimental Medicine Early Development, Oncology Therapeutic Area for Janssen Research and Development. Prior to Janssen, Dr. Takimoto was Senior Director of Translational Medicine of Ortho Biotech Oncology Research and Development. He has over thirty years of experience in industry and academia, including academic positions at the University of Texas Health Science Center at San Antonio, the National Cancer Institute, and the Uniformed Services University of the Health Sciences. He has also served as a Commissioned Officer in the U.S. Public Health Service. Dr. Takimoto received a B.S. in Chemistry from Stanford University, a Ph.D. in Pharmacology from Yale University, and an M.D. from Yale University School of Medicine.
Ms. Tauber joined us in 2019 and serves as our Chief Human Resources Officer. Prior to joining us, Ms. Tauber was in charge of human resources at ARMO BioSciences, a biotechnology company, from before its initial public offering through its acquisition by Eli Lilly. Previously, she held human resources leadership positions at a variety of life science and high-technology companies, including Cellular Research (acquired by Becton Dickinson), Kapor Enterprises, Escalate, KIVA Software (acquired by Netscape/AOL) and Bay Networks (acquired by Nortel). Ms. Tauber’s career in human resources began with Bain & Company, where she led their West Coast recruiting efforts. She received a B.A. in Communications from Northern Arizona University.
Dr. Carroll joined us in 2015 and is our Distinguished Research Fellow in Preclinical Sciences. Previously, Dr. Carroll spent 17 years in various scientific and leadership positions at Xoma, a biotechnology company, including Vice President of Preclinical Research and Scientific and Product Development. Dr. Carroll received a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Microbiology from the University of California, Los Angeles. He also completed a post doctorate in Microbiology at the University of California, Los Angeles, and he was an Assistant Professor in the Department of Microbiology and Molecular Genetics at Harvard Medical School.
Dr. Peterson joined us in 2017 and serves as our Senior Vice President of Process Sciences and Manufacturing. Dr. Peterson also served as Senior Director, Manufacturing at MabVax Therapeutics, a biotechnology company, from 2015 to 2017 and as Senior Director, Upstream Process Development and Manufacturing at Ambrx, a biotechnology company, from 2014 to 2015. Dr. Peterson has also served in manufacturing, scientific and leadership positions at Bristol-Myers Squibb, Eli Lilly, Celgene and Shire. Dr. Peterson received a B.S. in Chemical Engineering from the University of Colorado, Boulder and a Ph.D. in Chemical Engineering from Purdue University. He also completed a post doctorate at the University of Minnesota, BioProcess Technology Institute.
Dr. Sinclair joined us in 2018 and serves as our Vice President of Immuno-oncology. Prior to joining us, Dr. Sinclair served as Senior Director, Oncology Research at Northern Biologics, a biotechnology company, from 2015 to 2018. He also previously served in various scientific and leadership positions at Amgen, including most recently as Scientific Director, Oncology Research, from 2011 to 2015. Dr. Sinclair received a B.Sc. in Molecular Biology from the University of Edinburgh and a Ph.D. in Hematology/Molecular Biology from the National Institute for Medical Research/University College London.
Mr. Graffagnino has served as our Vice President of Legal Affairs since 2021. Mr. Graffagnino spent over two decades in private legal practice in Silicon Valley providing corporate and securities advice to technology companies as a Partner at the law firm of GCA Law Partners LLP. He began his legal career as an Associate in the Washington, D.C. office of Skadden Arps Slate Meagher & Flom LLP and became a Partner in the San Francisco office of Pillsbury Winthrop Shaw Pittman LLP. Mr. Graffagnino received a B.A. in Political Economy from Williams College and a J.D. from Georgetown University Law Center.
Dr. Haanes has served as our Vice President of Intellectual Property since 2019. Dr. Haanes spent the past 19 years in private legal practice in the Washington D.C. area, providing intellectual property services to a broad spectrum of biotechnology and pharmaceutical companies. Most recently she practiced as a Partner at the law firm of FisherBroyles, LLP, and prior to that was a Partner at Thompson Coburn LLP and a Director at Sterne Kessler Goldstein & Fox, PLLC. Prior to entering law school, Dr. Haanes conducted virology research as a scientist at Heska Corporation. She received a B.S. in Biology from the University of Michigan, a Ph.D. in Microbiology from the University of Minnesota, and a J.D. from the University of Colorado.
Mr. Harigopal has served as our Vice President of Information Technology since 2021. Prior to IGM, he served as Senior Director of IT at Cytokinetics, a public biotech focused on cardiovascular and neuromuscular diseases, where he led IT business solutions. Prior to Cytokinetics, he was Director of IT at Pharmacyclics, a public, commercial-stage biotech acquired by AbbVie, where he led enterprise business applications and web-mobile technologies. TS also spent nearly 12 years at Johnson & Johnson’s medical devices division, Lifescan, where he held IT roles of increasing responsibility in both the U.S. and Europe. Mr. Harigopal a Bachelor’s degree in Finance and Commerce from the University of Bombay, India and an M.B.A. from California State University, East Bay.
Dr. Humke has served as our Vice President of Clinical Development, Apoptosis since 2019. Prior to joining us, Dr. Humke was Senior Medical Director at Genentech in Research & Early Clinical Development where he led numerous clinical programs evaluating antibody drug conjugates for multiple myeloma, lung, ovarian, and endometrial cancer. He also oversaw multiple small molecule inhibitor programs for multiple myeloma, lung and breast cancer. Prior to joining Genentech, he was an Instructor of Medicine in the Division of Oncology at the Stanford University School of Medicine where he conducted research and clinical studies from 2009-2011. Dr. Humke received a B.S. from Brown University and an M.D., Ph.D. from the University of Michigan. Dr. Humke completed his internal medicine residency at Washington University in St. Louis (Barnes-Jewish Hospital) and a medical oncology fellowship at Stanford University.
Lisa has served as our Vice President of Regulatory Affairs since 2021. Her career spans 33 years including 23 years in regulatory affairs. Prior to joining IGM, Ms. Wax held the position of Head of Regulatory Affairs within the Oncology Early Development division at AbbVie where she led a team of 8 regulatory professionals and was responsible for a portfolio of approximately 30 programs. Prior to AbbVie, she held regulatory positions at several biotech companies including Genentech, Protein Design Labs, Anergen, Genitope and Fibrogen. In addition to early stage work, Ms. Wax has worked on several BLAs/sBLAs during her career including Empliciti, Herceptin and Avastin. Before transitioning into regulatory affairs, she worked for 10 years in discovery research at Applied Immune Sciences. Ms. Wax received her B.S. in Animal Science at Cornell University.